Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman Sells 8,426 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $230,114.06. Following the completion of the transaction, the general counsel now owns 146,126 shares of the company’s stock, valued at $3,990,701.06. This represents a 5.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phreesia Stock Down 0.2 %

Shares of NYSE PHR opened at $27.29 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a fifty day moving average of $23.77 and a 200-day moving average of $22.94. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $29.16.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.58) earnings per share. On average, sell-side analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PHR. International Assets Investment Management LLC raised its position in Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares during the period. Lombard Odier Asset Management USA Corp acquired a new stake in shares of Phreesia in the second quarter valued at about $202,000. Point72 DIFC Ltd purchased a new stake in shares of Phreesia during the 2nd quarter valued at about $209,000. XTX Topco Ltd acquired a new position in Phreesia during the 3rd quarter worth approximately $247,000. Finally, Hsbc Holdings PLC purchased a new position in Phreesia in the 2nd quarter worth approximately $301,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on PHR shares. Citigroup upped their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Robert W. Baird lowered their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. KeyCorp lifted their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Truist Financial increased their price target on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $31.00.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.